Aptinyx Revenue and Competitors
Estimated Revenue & Valuation
- Aptinyx's estimated annual revenue is currently $1M per year.
- Aptinyx received $70.0M in venture funding in December 2017.
- Aptinyx's estimated revenue per employee is $111,111
- Aptinyx's total funding is $268.3M.
- Aptinyx's current valuation is $198.4M. (January 2022)
Employee Data
- Aptinyx has 9 Employees.
- Aptinyx grew their employee count by -57% last year.
Aptinyx's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Sr. VP, Clinical and CMC Operations | Reveal Email/Phone |
2 | VP, Program Management and Chief Staff | Reveal Email/Phone |
3 | VP Chemistry R&D | Reveal Email/Phone |
4 | VP, Program Management & Chief Staff | Reveal Email/Phone |
5 | Associate Director, Program Management | Reveal Email/Phone |
6 | Senior Director, Regulatory and Quality | Reveal Email/Phone |
7 | Chief Financial Officer & Chief Business Officer | Reveal Email/Phone |
8 | Senior Director Research | Reveal Email/Phone |
9 | Senior Clinical Operations Study Manager | Reveal Email/Phone |
10 | Executive Chairman | Reveal Email/Phone |
Aptinyx Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $2.8M | 18 | -14% | N/A | N/A |
#2 | $0.8M | 5 | 0% | N/A | N/A |
#3 | $2M | 13 | 0% | N/A | N/A |
#4 | $707.3M | 2852 | 14% | $1.1B | N/A |
#5 | $1.7M | 11 | 0% | N/A | N/A |
#6 | $32.6M | 210 | 6% | N/A | N/A |
#7 | $2.6M | 17 | 6% | N/A | N/A |
#8 | $1.1M | 7 | -30% | N/A | N/A |
#9 | $1.4M | 9 | -10% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Aptinyx?
Welcome to our company page and thank you for your interest in Aptinyx Inc. Aptinyx is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need. At Aptinyx, we remain committed and responsive to our employees. We offer an engaging work environment, challenging work assignments, and competitive compensation and benefits. If you are interested in learning more, please visit our website at www.aptinyx.com.
keywords:N/A
$268.3M
Total Funding
9
Number of Employees
$1M
Revenue (est)
-57%
Employee Growth %
$198.4M
Valuation
N/A
Accelerator
Aptinyx News
According to Zacks, Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel,...
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Trouble continues for Aptinyx after it suddenly paused initiation of the higher dose arm of a phase 2b trial for a PTSD med.
Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights Completed enrollment in Phase 2b study of NYX-2925 in patients with painful diabetic peripheral neuropathy; results expected in early to mid 2Q 2022 Phase 2b fibromyalgia study and exploratory Phase 2 cognitive impairme ...
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has entered into a $50 million loan facility and security agreement with K2 HealthVentures (K2HV). The fund ...
Other Companies in Evanston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.1M | 9 | -76% | N/A |
#2 | $0.7M | 9 | 0% | N/A |
#3 | $1.3M | 10 | -17% | N/A |
#4 | $1M | 11 | -8% | N/A |
#5 | $1.8M | 11 | -42% | N/A |
Aptinyx Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2016-05-10 | $65.0M | A | New Leaf Venture Partners | Article |
| 2017-12-19 | $70.0M | B | Bain Capital Life Sciences | Article |